Corvus Pharmaceuticals Inc. (CRVS) Statistics & Valuation Metrics - Stocknear

Corvus Pharmaceuticals In...

NASDAQ: CRVS · Real-Time Price · USD
6.16
0.43 (7.50%)
At close: Sep 05, 2025, 3:59 PM
6.11
-0.81%
After-hours: Sep 05, 2025, 07:53 PM EDT

Corvus Pharmaceuticals Statistics

Share Statistics

Corvus Pharmaceuticals has 74.51M shares outstanding. The number of shares has increased by 23.28% in one year.

74.51M
23.28%
13.18%
50.28%
54.39M
5
n/a

Short Selling Information

The latest short interest is 9.29M, so 12.47% of the outstanding shares have been sold short.

9.29M
12.47%
15.78%
18.81

Valuation Ratios

The PE ratio is -5.24 and the forward PE ratio is -9.71. Corvus Pharmaceuticals's PEG ratio is -0.06.

-5.24
-9.71
0
592.3
10.02
-12.83
-0.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Corvus Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.03.

1.54
1.54
0.03
-0.04
-0.04
-15.1

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-2.01M
31
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 52.85% in the last 52 weeks. The beta is 0.51, so Corvus Pharmaceuticals's price volatility has been higher than the market average.

0.51
52.85%
4.66
4.78
73.4
730,270

Income Statement

n/a
-85K
-27.55M
-62.29M
-27.55M
-60.47M
-1.02
Full Income Statement

Balance Sheet

The company has 8.74M in cash and 1.12M in debt, giving a net cash position of 7.62M.

8.74M
1.12M
7.62M
-397.01M
89.46M
67.28M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -25.42M and capital expenditures 0, giving a free cash flow of -25.42M.

-25.42M
n/a
-25.42M
-0.42
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

CRVS does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for CRVS is $14, which is 127.3% higher than the current price. The consensus rating is "Buy".

$14
127.3%
Buy
4
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

20.95
2